Video Experimental Relacionado
Updated: May 6, 2026
07:27
Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
Published on: October 6, 2016
12.2K
Tratamiento de la enfermedad de Alzheimer en una persona que vive con el VIH
David B Clifford1, Tammie L S Benzinger2, Jee-Young Han1
1Department of Neurology Washington University St. Louis Missouri USA.
Alzheimer's & dementia (Amsterdam, Netherlands)
|February 20, 2026
Resumen
Las terapias anti-amiloideas (TAA) son prometedoras para el tratamiento de la enfermedad de Alzheimer (EA) en personas con VIH. Los primeros hallazgos sugieren que la AAT es segura y no interfiere con el tratamiento del VIH, ofreciendo esperanza para una población de VIH que envejece.
Área de la Ciencia:
- Neurología Neurología.
- Enfermedades infecciosas Enfermedades infecciosas.
- Geriatría La geriatría es la medicina de los ancianos.
Sus antecedentes:
- Las terapias modernas del virus de la inmunodeficiencia humana (VIH) permiten a las personas vivir más tiempo, alcanzando edades avanzadas.
- La enfermedad de Alzheimer (EA), un trastorno neurodegenerativo común, ahora se puede tratar con terapias antiamiloides (TAA).
- Los individuos VIH-positivos fueron excluidos de los ensayos clínicos de AAT, dejando desconocidos los datos de seguridad y eficacia en esta población.
Objetivo del estudio:
- Evaluar la seguridad y eficacia de AAT en un individuo con VIH bien controlado.
- Evaluar el impacto de la AAT en el tratamiento continuo del VIH.
Principales métodos:
- Un informe de caso que detalla la progresión de la enfermedad de Alzheimer en 10 años en una persona con VIH.
- Utilizó evaluaciones clínicas exhaustivas y análisis de biomarcadores.
- Documentó la administración de AAT y sus efectos en el manejo del VIH.
Principales resultados:
- El diagnóstico de EA se confirmó a través de evidencia clínica y de biomarcadores consistentes.
- AAT se administró sin ninguna complicación reportada.
- La terapia para el VIH se mantuvo efectiva durante todo el período del estudio.
Conclusiones:
- Este caso proporciona evidencia inicial para el uso seguro de AAT en personas con VIH.
- AAT no parece afectar negativamente el tratamiento del VIH.
- Los hallazgos son relevantes para la creciente población de personas mayores con VIH que pueden desarrollar AD.
Videos de Conceptos Relacionados
01:10Retrovirus Life Cycles
43.1K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.1K
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
01:23Alzheimer Disease ll: Pathophysiology
42
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42